Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018
Basel, 04 October 2018 Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018 Baloxavir marboxil – a first-in-class, single-dose, investigational oral medicine – is the first potential influenza treatment in clinical trials to demonstrate a clinically meaningful benefit for people highly vulnerable... Read more